AZACITIDINE SANDOZ^®
(azacitidine)
NOVARTIS
HK Reg. No. HK-68489 (13 Dec, 2024)
Composition:¹

• Azacitidine Sandoz is supplied in a sterile powder form for reconstitution as a suspension for subcutaneous injection or for intravenous infusion. Each vial contains 100 mg azacitidine

Indication:¹

• Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS) according to the International Prognostic Scoring System (IPSS)

• Chronic Myelomonocytic Leukemia (CMMoL [10–29% marrow blasts without Myeloproliferative Disorder])

• Acute Myeloid Leukemia (AML) with 20–30% blasts and multi-lineage dysplasia, according to World Health Organization (WHO) Classification, in whom allogenic stem cell transplantation is not indicated

References

1. Therapeutic Goods Administration, Australia. Product Information. 18 March 2024. Available from:  https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2022-PI-01599-1&d=20250103172310101. [Accessed 3 January 2025]. 2. European Medicines Agency. Summary of Product Characteristics. Available from: https://ec.europa.eu/health/documents/community-register/2023/20231201161202/anx_161202_en.pdf. [Accessed 3 January 2025].  3. EMC. Quofenix 300 mg powder for concentrate for solution for infusion SmPC. Available from: https://www.medicines.org.uk/emc/product/11481/smpc#about-medicine. [Accessed 3 January 2025].  4. European Medicines Agency. Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf. [Accessed 3 January 2025].